Trogenix
22 employees on LinkedIn · 3 known investors
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while triggering an immune response. Its pipeline targets solid tumours, including a Phase I/II gene therapy (TGX-007) for glioblastoma, with potential applications in regenerative medicine.
Investors · 3
Frequently asked questions
- What does Trogenix do?
- Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while triggering an immune response. Its pipeline targets solid tumours, including a Phase I/II gene therapy (TGX-007) for glioblastoma, with potential applications in regenerative medicine.
- Who are Trogenix's investors?
- Trogenix's investors include ACADEMY INVESTOR, LongeVC, AIN Ventures.